严重急性呼吸道综合征冠状病毒疫苗研究现状

冠状病毒被认为是新近爆发的严重急性呼吸道综合征的病原体.迄今公共数据库中已发表了不同国家和地区分离的12个SARS病毒株基因组完整序列.突起蛋白是冠状病毒的主要抗原,包含许多抗原决定簇.SARS冠状病毒突起蛋白的相对保守性为有效疫苗的开发奠定了很好的研究基础.灭活或减毒的冠状病毒疫苗存在一定的局限性和危险性.开展基因工程疫苗和核酸疫苗的制备研究以及相关候选疫苗的联合应用研究将是一个切实可行的途径.

Current Research on SARS Coronavirus Vaccine

A novel coronavirus has been identified to be associated with the newly outbreak of severe acute respiratory syndrome (SARS). To date 12 whole genome sequences from various samples are available in public-domain database. Spike protein of coronavirus is considered to be the major antigen and contains many potential antigenicity domains. The relatively low mutation rate in spike protein provides high opportunity for effective vaccine development. Since inactivated or attenuated coronavirus holds some potential limitations and risks to prepare and to inoculate, the current best hope for protection is to combine a protein vaccine (i.e., a purified SARS coronavirus spike protein) with a "vectored" vaccine, consisting of a plasmid or a harmless virus, such as recombinant adenovirus which has been genetically engineered to produce coronavirus spike protein.